Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31400174 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL11441576 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL16692078 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7037381 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL17634037 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL887187 | 1.00 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL667447 | 0.98 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL16283432 | 0.94 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL535583 | 0.94 | HTT (0.74) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.94 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911795-B1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2025-10-01 | — | — | EP | claimed |
| CN-113646479-B | Method for strengthening non-keratin fibers and use thereof | 埃斯普投资有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-9150602-B2 | Precursor used for labeling hepatorcyte receptor and containing trisaccharide and diamide demercaptide ligand, method for preparing the same, radiotracer and pharmaceutical composition of the same | ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-10-06 | — | — | US | claimed |
| US-20140031533-A1 | PRECURSOR USED FOR LABELING HEPATORCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DIAMIDE DEMERCAPTIDE LIGAND, METHOD FOR PREPARING THE SAME, RADIOTRACER AND PHARMACEUTICAL COMPOSITION OF THE SAME | ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2014-01-30 | — | — | US | claimed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4634197-A1 | COMPOSITIONS AND METHODS FOR CHEMOPROTEOMICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4573102-A2 | COMPOSITIONS AND METHODS FOR CHEMOPROTEOMIC REAGENT SYNTHESIS AND APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| CN-114929729-B | Nucleic acid complex and pharmaceutical composition containing the same | 卫材R&D管理有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-0501250-A1 | Fucose-marked batracylin derivatives | BAYER AG (DE) | 1992-09-02 | — | — | EP | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
| US-4668769-A | Oxa- and azahomocyclostatine polypeptides | PFIZER INC. | 1987-05-26 | — | — | US | disclosed |
| EP-0211580-A2 | Renin inhibiting polypeptides and intermediates therefor | PFIZER INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4599198-A | Intermediates in polypeptide synthesis | PFIZER INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4550163-A | Ligand analog-irreversible enzyme inhibitor conjugates | ABBOTT LABORATORIES (US) | 1985-10-29 | — | — | US | disclosed |
| US-4273866-A | IMMUNOASSAY FOR QUANTITATIVE ANALYSIS OF ACETYLCHOLINESTERASE | ABBOTT LABORATORIES (US) | 1981-06-16 | — | — | US | disclosed |
| US-4228274-A | 1-Substituted glycopyranosides | MERCK & CO., INC. (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | HTT 1719/4885TGM2 1041/4885LMNA 4564/4885 |
| US-20140031533-A1 | PRECURSOR USED FOR LABELING HEPATORCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DIAMIDE DEMERCAPTIDE LIGAND, METHOD FOR PREPARING THE SAME, RADIOTRACER AND PHARMACEUTICAL COMPOSITION OF THE SAME | ASGR1, M6PR, DDOST | HTT 3450/4885TGM2 776/4885LMNA 4135/4885 |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | HTT 982/4885TGM2 659/4885LMNA 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.